Day One Biopharmaceuticals Inc (OQ:DAWN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 2000 Sierra Point Parkway, Suite 501
BRISBANE CA 94080-1930
Tel: N/A
Website: https://dayonebio.com
IR: See website
<
Key People
Garry A. Nicholson
Chairman of the Board
Jeremy Bender
President, Chief Executive Officer, Director
Samuel Blackman
Co-Founder, Head of Research and Development
Charles N. York
Chief Financial Officer, Chief Operating Officer, Secretary
Lauren Merendino
Chief Commercial Officer
Raphael F. Rousseau
Chief Medical Officer
Business Overview
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing targeted therapies for patients of all ages with life threatening diseases. The Company seeks to identify, acquire and develop product candidates that target high-value oncogenic drivers in cancers with unmet needs, with an initial focus on pediatric patients. Its lead product candidate, tovorafenib (DAY101), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the MAPK pathway. It has initiated an open-label, multicenter, Phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib monotherapy or combination therapy, which consists of two substudies, such as Substudy 1 and Substudy 2.
Financial Overview
For the fiscal year ended 31 December 2023, Day One Biopharmaceuticals Inc revenues was not reported. Net loss increased 33% to $188.9M. Higher net loss reflects Research and development increase of 51% to $116.1M (expense), General and administrative - Balancing increase of 19% to $50.6M (expense), Stock-based Compensation in SGA increase of 33% to $25M (expense).
Employees: 155 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,013M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$206.03M as of Dec 31, 2023
Net annual income (TTM): -$188.92M as of Dec 31, 2023
Free cash flow (TTM): -$147.08M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 87,384,856 as of Feb 21, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.